A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.

开始日期2022-11-21

申办/合作机构

Ionis Pharmaceuticals, Inc.

100 项与 Olezarsen 相关的临床结果

登录后查看更多信息

100 项与 Olezarsen 相关的转化医学

登录后查看更多信息

100 项与 Olezarsen 相关的专利（医药）

登录后查看更多信息

项与 Olezarsen 相关的文献（医药）

2024-04-01·Current Opinion in Endocrinology, Diabetes & Obesity

APOC3 siRNA and ASO therapy for dyslipidemia

Review

作者: Chebli, Jasmine ; Larouche, Miriam ; Gaudet, Daniel

Purpose of reviewThe aim of this review is to present the clinical indications of apolipoprotein C-III (apoC3) inhibition in the therapeutic arsenal for the treatment of lipid disorders and associated risks and to compare the most advanced modalities of apoC3 inhibition currently available or in development, specifically APOC3 antisense oligonucleotides (ASO) and small interfering RNA (siRNA).Recent findingsApoC3 inhibition significantly decreases triglyceride levels by mechanisms coupling both lipoprotein lipase (LPL) upregulation and LPL-independent mechanisms. The main apoC3 inhibitors in advanced clinical development are the GalNAc-ASO olezarsen and the GalNAc-siRNA plozasiran. Clinical studies conducted with volanesorsen, the olezarsen precursor, showed a favorable effect on hepatic steatosis (nonalcoholic fatty liver disease, NAFLD). Olezarsen does not appear to be associated with the main side effects attributed to volanesorsen including thrombocytopenia. Plozasiran is in advanced clinical development and requires subcutaneous injection every 3 months and present to-date an efficacy and safety profile comparable to that of the monthly ASO.SummaryInhibition of apoC3 is effective across all the spectrum of hypertriglyceridemia, might have a favorable effect on hepatic steatosis (NAFLD) and the effect of apoC3 inhibition on cardiovascular risk is not limited to its effect on plasma triglycerides. APOC3 GalNAc-conjugated ASO and siRNA are both effective in decreasing plasma apoC3 and triglyceride levels.

2024-01-01·Journal of Lipid and Atherosclerosis

Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Review

作者: Wu, Qian-Yan ; Zhong, Yi-Ming ; Li, Yan-Hong ; Tomlinson, Brian

Apolipoprotein C3 (apoC3) and angiopoietin-like protein 3 (ANGPTL3) inhibit lipolysis by lipoprotein lipase and may influence the secretion and uptake of various lipoproteins. Genetic studies show that depletion of these proteins is associated with improved lipid profiles and reduced cardiovascular events so it was anticipated that drugs which mimic the effects of loss-of-function mutations would be useful lipid treatments. ANGPTL3 inhibitors were initially developed as a treatment for severe hypertriglyceridaemia including familial chylomicronaemia syndrome (FCS), which is usually not adequately controlled with currently available drugs. However, it was found ANGPTL3 inhibitors were also effective in reducing low-density lipoprotein cholesterol (LDL-C) and they were studied in patients with homozygous familial hypercholesterolaemia (FH). Evinacumab targets ANGPTL3 and reduced LDL-C by about 50% in patients with homozygous FH and it has been approved for that indication. The antisense oligonucleotide (ASO) vupanorsen targeting ANGPTL3 was less effective in reducing LDL-C in patients with moderate hypertriglyceridaemia and its development has been discontinued but the small interfering RNA (siRNA) ARO-ANG3 is being investigated in Phase 2 studies. ApoC3 can be inhibited by the ASO volanesorsen, which reduced triglycerides by >70% in patients with FCS and it was approved for FCS in Europe but not in the United States because of concerns about thrombocytopaenia. Olezarsen is an N-acetylgalactosamine-conjugated ASO targeting apoC3 which appears as effective as volanesorsen without the risk of thrombocytopaenia and is undergoing Phase 3 trials. ARO-APOC3 is an siRNA targeting apoC3 that is currently being investigated in Phase 3 studies.

2023-10-01·Current atherosclerosis reports

Updates in Drug Treatment of Severe Hypertriglyceridemia.

Review

作者: Gouni-Berthold, Ioanna ; Berthold, Heiner K ; Schwarz, Jonas

PURPOSE OF REVIEWTo provide an insight into the new pharmacological options for the treatment of severe hypertriglyceridemia (sHTG).RECENT FINDINGSsHTG is difficult to treat. The majority of the traditional pharmacological agents available have limited success in both robustly decreasing triglyceride levels and/or in reducing the incidence of acute pancreatitis (AP), the most severe complication of sHTG. Therapeutic options with novel mechanisms of action have been developed, such as antisense oligonucleotides (ASO) and small interfering RNA (siRNA) targeting APOC3 and ANGPTL3. The review discusses also 2 abandoned drugs for sHTG treatment, evinacumab and vupanorsen. The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndrome (FCS) in Europe. Olezarsen, an N-acetylgalactosamine (GalNAc)-conjugated ASO with the same target, seems to have a better safety and efficacy profile. siRNA targeting APOC3 and ANGPTL3, namely ARO-APOC3 and ARO-ANG3, are also promising for the treatment of sHTG. However, the ultimate clinical goal of any sHTG treatment, the decrease in the risk of AP, has not been definitively achieved till now by any pharmacotherapy, either approved or in development.

项与 Olezarsen 相关的新闻（医药）

2024-04-27

·梅斯医学

强效降血脂近100%；控制好血压，可将痴呆症风险降低24%… | 前沿荟萃

高血压和血脂异常（以血清胆固醇或甘油三酯水平升高为主要表现）为心血管疾病发病和死亡的两项主要危险因素。目前，中国患有高血压和血脂异常的人数已高达数亿，中国18岁及以上成人的高血压和血脂异常患病率分别为27.9%和40.4%，严重影响人们的身心健康和生活质量。我们梳理了2024年1~4月全球权威期刊（IF≥20）发表的223篇血压和血脂相关研究，并和大家分享4月共5篇较为有代表性的研究。这些研究包括：1. 新型降脂药1年2次，可将“坏胆固醇”水平降低60%。2. Olezarsen每月一针用于中重度高甘油三酯血症，可将甘油三酯降低高达53.1%。3. Plozasiran每季度一针用于重度高甘油三酯血症，可将甘油三酯降低86%。4. RNAi长效疗法降脂近100%。5. 控制好血压，还可防痴呆症。血脂相关研究打一针管半年！新型降脂药，可将“坏胆固醇”水平降低60%对于那些在接受他汀类药物治疗后胆固醇水平仍然较高、或无法耐受他汀类药物治疗的患者来说，新型降胆固醇药物的治疗至关重要。阻断前蛋白转化酶枯草杆菌蛋白酶/kexin9型（PCSK9）的药物已被证明是高效且耐受性良好的治疗高胆固醇血症的方法。在不同的患者群体中，无论既往是否使用过他汀类药物治疗，这类疗法均能将低密度脂蛋白胆固醇（LDL-C）水平持续降低50%~70%，并能改善心血管结局。英克司兰钠注射液（inclisiran）是一种靶向PCSK9的新型小干扰RNA（siRNA）降脂疗法，可抑制PCSK9的合成，作用时间长，给药方便（1年2次皮下注射）。发表于JACC的一项研究显示，与常规治疗相比，“inclisiran-first”策略使LDL-C从基线至第330天显著降低（LDL-C百分比变化：-60.0% vs. -7.0%；P<0.001）。此外，“inclisiran-first”组的他汀类药物停药率并不劣于常规治疗组（6.0% vs. 16.7%；治疗差异-10.6%，97.5% CI -18.3%~-3.0%）(非劣效CI界值+15.0%）。每月一针或每季度一针强效降血脂，甘油三酯降幅可达86% 甘油三酯水平升高与心血管事件和急性胰腺炎风险增加相关。载脂蛋白C-III（APOC3）主要在肝脏合成并增加甘油三酯水平。先前的遗传分析表明，APOC3基因功能缺失突变与甘油三酯水平降低和缺血性心血管疾病风险降低独立相关，这表明APOC3是降低甘油三酯和减少心血管疾病的潜在治疗靶点。1.在中重度高甘油三酯血症患者中，olezarsen每月一针将甘油三酯水平降低高达53.1%Olezarsen为靶向APOC3 mRNA的反义寡核苷酸，可每月皮下注射一次，已在1期和2期小型试验中进行了评估。发表于NEJM的一项研究（BRIDGE-TIMI 73a试验）结果显示，在主要为中度高甘油三酯血症（甘油三酯水平：150~499 mg/dL）合并心血管风险升高的患者中，与安慰剂相比，olezarsen 50 mg和80 mg治疗可显著降低甘油三酯水平：olezarsen 50 mg组、80 mg组以及安慰剂组的甘油三酯水平较基线分别平均下降57.1%（95% CI，50.9%~63.2%）、60.9%（95% CI，54.7%~67.1%）和7.8%（95% CI，0.2%~15.3%）。与安慰剂组相比，olezarsen 50 mg组和80 mg组分别将甘油三酯水平降低了49.3%（95% CI，39.5%~59.0%）和53.1%（95% CI，43.4%~62.9%）（P均<0.001）。2. 在重度高甘油三酯血症患者中，每季度一针可将甘油三酯水平降低86%Plozasiran（ARO-APOC3）是一种针对APOC3基因的小干扰RNA（siRNA），可每季度皮下注射一次。一项1期研究数据显示，12周内，单次皮下注射plozasiran可显著且持久降低APOC3水平，进而也可持续降低甘油三酯水平。发表于JAMA Cardiology的一项研究（SHASTA-2）结果显示，在重度高甘油三酯血症（甘油三酯水平：≥500 mg/dL）患者中，plozasiran治疗可显著降低甘油三酯和APOC3水平：1）第24周时，以最小二乘法计，经安慰剂校正后，使用plozasiran治疗使甘油三酯水平呈剂量依赖性降低：plozasiran 10 mg组：-49%（95% CI，-64.0%~-33.7%；P<0.001）；plozasiran 25 mg组：-53%（95% CI，-68.1%~-38.0%；P<0.001）；plozasiran 50 mg组：-57%（95% CI，-71.9%~-42.1%；P<0.001）。2）此外，在未经安慰剂校正下，甘油三酯和APOC3水平自基线可平均最高下降86%和90%。降脂近100%！RNAi长效疗法，疗效至少维持7个月脂蛋白(a)[Lp(a)]是动脉粥样硬化性心血管疾病（ASCVD）的致病危险因素之一，同时可能是心血管残余风险的潜在干预靶点。Zerlasiran是一种靶向Lp(a)肝脏合成的小干扰RNA（siRNA）。发表于JAMA的一项研究结果显示，zerlasiran安全性和耐受性良好，能在不频繁给药的情况下降低脂蛋白(a)水平。单次给药后365天，安慰剂组脂蛋白(a)水平的中位变化为14%（IQR，13%~15%），zerlasiran 300 mg组中位变化为-30%（IQR，-51%~ -18%），zerlasiran 600 mg组中位变化为-29%（IQR，-39%~-7%）。多次给药后，安慰剂组脂蛋白(a)水平的最大中位变化为19（IQR，-17~28）nmol/L，zerlasiran 200 mg组为-258（IQR，-289~-188）nmol/L，300 mg组为-310（IQR，-368~-274）nmol/L，450 mg组为-242（IQR，-343~-182）nmol/L，最大中位变化百分比分别为：7%、-97%、-98%和-99%，在给药后201天分别减弱至0.3%、-60%、-90%和-89%。血压相关研究控制好血压，还可防痴呆症！有研究证据指出，控制好高血压可以减少患痴呆症的风险。不过，这一证据是否适用于一般人群中的老年人仍不确定。发表于JACC的一项研究结果显示，在老年人群中，抗高血压药物治疗与痴呆症风险降低相关。与接受极低程度抗高血压药物治疗的患者相比，接受低、中和高程度治疗的患者的痴呆症风险分别降低2%（95% CI：-4%~7%）、12%（95% CI：6%~17%）和24%（95% CI：19%~28%）。对于高龄（≥85岁）和体弱患者（即1年内死亡风险较高的患者），结果也是如此。参考资料（可上下滑动查看）[1] Koren MJ, et al., (2024). An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol, doi: 10.1016/j.jacc.2024.03.382. [2] Bergmark BA, et al., (2024). Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med, doi: 10.1056/NEJMoa2402309.[3] Gaudet D, et al., (2024). Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol, doi: 10.1001/jamacardio.2024.0959. [4] Nissen SE, et al., (2024). Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA, doi: 10.1001/jama.2024.4504. [5] Rea F, et al., (2024). Risk of Dementia During Antihypertensive Drug Therapy in the Elderly. J Am Coll Cardiol, doi: 10.1016/j.jacc.2024.01.030.撰文 | 医学新视点编辑 | 阿拉斯加宝● 最新研究：这种常见的维生素，能有效保护大脑，“逆转”认知衰退！● 一喝酒就脸红，易患癌还早衰？Nature子刊最新研究揭开：喝酒“上脸”与衰老加速之间的关联● 重磅！真把护工取消了！福建、天津等多地医院推出“无陪护制度”，一天只收60元护理费！家属：真省心，病人24小时全交给医院……版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

siRNA临床结果临床1期临床2期信使RNA

2024-04-16

·FiercePharma

Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData

“If approved, plozasiran offers hope for the dyslipidemia drug market. According to GlobalData, plozasiran is forecasted to launch in 2026 and is a promising pipeline drug for the treatment of dyslipidemia,” said Shireen Mohammad, Ph.D., a cardiovascular and metabolic disorders analyst at GlobalData. With the ink still drying on Arrowhead Pharmaceuticals’ recent announcement of successful 48-week results in a phase 2 trial of its RNAi drug candidate plozasiran, analysts are already projecting much longer-term success for the drug. If approved, plozasiran could reach sales of around $707 million by 2032, according to a recent report from GlobalData. Those revenues would come from the drug’s ability to fill a current gap in the market: It’s shown promise in reducing triglycerides and the protein APOC3, meaning it could be used to treat many forms of dyslipidemia, a family of diseases in which lipids or lipoproteins are found in abnormally high or low amounts in the blood, the presence of which is a known risk factor for heart disease. Arrowhead’s latest results came from a study focused on patients with severe hypertriglyceridemia (SHTG) who have limited treatment options, according to Shireen Mohammad, Ph.D., a cardiovascular and metabolic disorders analyst at GlobalData, citing key opinion leaders interviewed for the report. Those leaders also suggested that the drug prospect could be used to treat severe genetic disorders associated with heightened levels of triglycerides, such as familial chylomicronemia syndrome (FCS) and familial hypercholesterolemia. As Mohammad noted in the report, "there are no FDA-approved therapies to treat FCS. Therefore, there is a critical unmet need for new FCS treatments that effectively lower triglyceride levels and prevent the complications associated with this disease.” Other ongoing studies of plozasiran have recruited patients with mixed dyslipidemia—where a phase 2 trial recently wrapped up—and FCS, for which a phase 3 trial is currently underway. Last year, Arrowhead received a fast-track designation from the FDA for plozasiran’s use in reducing triglycerides in people with FCS. “If approved, plozasiran offers hope for the dyslipidemia drug market. According to GlobalData, plozasiran is forecasted to launch in 2026 and is a promising pipeline drug for the treatment of dyslipidemia,” Mohammad said. The data Arrowhead shared earlier this month from the SHTG-focused trial demonstrated how participants fared at the 48-week mark after receiving a second and final dose of plozasiran at Week 12. Though APOC3 and triglycerides both began to creep back up in the following weeks, they still remained lower in the plozasiran group than among those assigned to placebo, with a 58% drop in triglycerides at Week 48 compared to just a 7% drop among the placebo group. At 24 weeks in the study, the drop in triglycerides was 70%. With the company now planning to move into phase 3 trials of plozasiran in SHTG and mixed dyslipidemia, and the FCS trial already in process, it’s hot on the heels of Ionis Pharmaceuticals. Ionis has its own phase 3 trials in SHTG underway and has already wrapped up a phase 3 study in FCS, all centering on its APOC3 RNA-targeted investigational Ligand Conjugated Antisense (LICA) medicine olezarsen.

临床3期临床2期临床结果快速通道

2024-04-13

·生物谷

NEJM｜一种实验性疗法或能进一步降低高风险患者机体中甘油三酯的水平

高甘油三酯血症，即血液中脂质浓度过高，极大地提升了罹患心脏病发作、中风及急性胰腺炎的风险。目前的可用药物，包括他汀类药物、依泽替米贝（ezetimibe）、贝特类(fibrates)和处方类的Ω-3脂肪酸，通常能将机体甘油三酯的水平降低10%至40%，这些疗法能有所帮助，但并不足以预防每个人机体的心血管疾病事件。近日，一篇发表在国际杂志New England Journal of Medicine上题为“Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk”的研究报告中，来自美国布莱根妇女医院等机构的科学家们通过进行一项安慰剂对照双盲试验，结果表明，一种实验性的疗法或能进一步降低机体血液中的甘油三酯水平，此研究成果已在2024年的美国心脏病学会年会上公开展示。在这项研究中，科研团队采用随机双盲安慰剂对照试验设计，将154名已接受基础降脂治疗、并诊断为重度或极高甘油三酯血症的患者分为三个组别，分别接受50mg、80mg剂量的olezarsen治疗，或是接受安慰剂治疗。olezarsen是一种反义寡核苷酸，其能通过靶向作用APOC3基因的mRNA来抑制APOC3基因的表达，APOC3是一种与高水平甘油三酯相关的特殊基因。所有参与者的皮下药物治疗每隔四周进行一次，疗程持续一年。图片来源：https://www.nejm.org/doi/10.1056/NEJMoa2402309相比安慰剂治疗而言，Olezarsen在50mg剂量下能将甘油三酯的水平降低49%，在80mg剂量下能降低53%，此外，该实验性药物还展现出对载脂蛋白B和非高密度脂蛋白胆固醇（non-HDL cholesterol）的显著降低效果，分别使其水平下降18%-18.5%和23%-25%。这两项指标均是促进动脉粥样硬化斑块形成的决定性因素。尽管研究人员还需要更大规模和更长期的研究来进一步评估olezarsen在预防心脏病发作和中风中的疗效和安全性，但此次研究无疑开启了一条改善心血管疾病高风险人群健康状况的新通道。研究者指出，本文研究结果表明，靶向作用APOC3 mRNA或许是降低机体甘油三酯水平，并潜在降低心脏病发作和中风风险的有希望新途径。综上，在心血管疾病风险升高的中度高甘油三酯血症患者中，olezarsen能显著降低其机体甘油三酯、载脂蛋白B和非高密度脂蛋白胆固醇的水平，且并不会产生重大的安全性问题。参考文献：Brian A. Bergmark, M.D., Nicholas A. Marston, M.D., M.P.H., Thomas A. Prohaska, M.D., Ph.D., et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2402309本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

信使RNA寡核苷酸临床研究

100 项与 Olezarsen 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
家族性乳糜微粒血症综合征	临床3期	荷兰	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	加拿大	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	意大利	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	挪威	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	美国	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	匈牙利	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	斯洛伐克	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	英国	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	西班牙	Ionis Pharmaceuticals, Inc.	2020-11-16
家族性乳糜微粒血症综合征	临床3期	瑞典	Ionis Pharmaceuticals, Inc.	2020-11-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03385239 (CTgov)	临床2期	心血管疾病 \| 高甘油三酯血症	114	Placebo (Pooled Placebo)	(獵餘廠願獵網壓襯顧淵) = 觸獵艱構遞繭選壓觸淵鹹窪淵觸範醖醖願餘餘 (廠艱觸遞網繭齋築醖廠, 簾獵窪積襯網蓋顧鹹鹹 ~ 鹽夢積繭憲餘觸鑰壓艱) 更多	-	2023-01-11
				ISIS 678354 (Cohort A: ISIS 678354: 10 mg Q4W)	(獵餘廠願獵網壓襯顧淵) = 糧獵簾繭衊網廠餘膚壓鹹窪淵觸範醖醖願餘餘 (廠艱觸遞網繭齋築醖廠, 衊膚鹽憲鏇夢壓壓鹹夢 ~ 齋餘夢觸衊顧膚廠繭窪) 更多
NCT04568434 (Pubmed)	临床3期	胰腺炎 \| 家族性乳糜微粒血症综合征	66	Olezarsen 80 mg	鬱網鹽窪齋顧餘製餘壓(選範艱構壓夢夢鹹鬱簾) = 製鬱醖鏇餘淵壓構網繭壓糧衊蓋鏇淵醖鑰齋窪 (窪鹽膚遞鬱鹽衊顧憲壓, -69.1 ~ -17.9) 更多	-	2024-04-07
				Olezarsen 50 mg	鬱網鹽窪齋顧餘製餘壓(選範艱構壓夢夢鹹鬱簾) = 蓋鏇鏇鹹繭艱齋夢積壓壓糧衊蓋鏇淵醖鑰齋窪 (窪鹽膚遞鬱鹽衊顧憲壓, -47.2 ~ 2.5) 更多
NCT04568434 (BALANCE, Corporate Publications 1 \| Corporate Publications 2) 人工标引	临床3期	家族性乳糜微粒血症综合征	66	Olezarsen	- 达到更多	积极	2023-09-26
				Placebo
NCT02900027 (Pubmed) 人工标引	临床1/2期	高甘油三酯血症 \| 心血管疾病	-	AKCEA-APOCIII-LRx	(廠築觸醖夢餘襯範醖選) = one injection site reaction of mild erythema, and no flu-like reactions, platelet count reductions, liver, or renal safety signals 築觸壓簾鑰蓋艱夢衊壓 (鹽鏇鬱鑰觸鹽範築壓築 ) 更多	积极	2019-09-01
				Placebo
NCT03385239 (Pubmed \| Eur Heart J) 人工标引	临床2期	高甘油三酯血症	114	AKCEA-APOCIII-LRx	(選繭鏇積憲願顧夢壓鏇) = 積遞蓋築遞夢鏇鹹窪廠鑰艱鹹觸獵窪餘鏇衊廠 (鏇繭蓋鏇鹹糧選齋網積 ) 更多	积极	2022-01-13
				saline placebo	(選繭鏇積憲願顧夢壓鏇) = 醖範壓構繭醖蓋鏇餘範鑰艱鹹觸獵窪餘鏇衊廠 (鏇繭蓋鏇鹹糧選齋網積 ) 更多
NCT05355402 (Literature) 人工标引	临床2期	高甘油三酯血症	154	Olezarsen (50-mg cohort)	(獵鏇繭鹹衊餘壓餘蓋糧) = 齋願醖鬱醖築簾範範鑰鑰繭構鹹廠齋蓋繭選糧 (醖積選餘艱餘襯築選醖 )	积极	2024-04-07
				Olezarsen (80-mg cohort)	(獵鏇繭鹹衊餘壓餘蓋糧) = 憲廠餘構遞網鏇蓋齋範鑰繭構鹹廠齋蓋繭選糧 (醖積選餘艱餘襯築選醖 )
NCT04568434 (Biospace) 人工标引	临床3期	家族性乳糜微粒血症综合征	66	olezarsen 80 mg	(淵醖襯範製蓋膚蓋壓鏇) = 壓築製襯選鏇鏇範鏇齋齋築齋衊築鑰鏇積鹹構 (夢淵觸衊夢繭壓糧艱餘 ) 达到更多	积极	2024-04-07
				olezarsen 50 mg	(淵醖襯範製蓋膚蓋壓鏇) = 蓋鑰獵淵醖製餘選觸顧齋築齋衊築鑰鏇積鹹構 (夢淵觸衊夢繭壓糧艱餘 ) 达到更多